VIVUS (VVUS) Qsymia Prescriptions Fall for Second Week; Promotion Still Ongoing

Prescriptions for VIVUS (Nasdaq: VVUS) Qsymia were light for a second-straight week, pressuring shares Monday.

Data from Symphony Health shows a 1 percent drop in Qsymia prescriptions for the week ended March 29th:

• Low-dose Qsymia TRx were at 1,540, from 1,557 the prior period;
  
  
• Medium-dose came in at 2,076, from a prior read of 2,200 prescriptions; and
  
  
• High-dose TRx came in at 116, from 90 the previous week.

Bloomberg Industries notes that low-dose is down 14.4 percent from a peak hit on February 8th. VIVUS is currently promoting an introductory Qsymia dose for no-cost, while VIVUS brings in no revenue on the promotion.

Shares of VIVUS are down 1.3 percent.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Anthropic hires Google chip veteran as it pushed into hardware - Bloomberg
• Citadel has shed over 80% of aggregate risk from Situational Awareness portfolio - CNBC
• FTC files amicus brief challenging Amgen's Enbrel patent acquisition